{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=11", "query": { "intervention": "5-Fluorouracil (5FU)", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1004, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5-Fluorouracil+%285FU%29&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T00:34:07.489Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02724202", "title": "Curcumin in Combination With 5FU for Colon Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Colon Cancer" ], "interventions": [ { "name": "Curcumin", "type": "DRUG" }, { "name": "5-flurorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-02-20", "completion_date": "2020-01-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724202" }, { "nct_id": "NCT00319683", "title": "A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "ADH300004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adherex Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-12-15", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00319683" }, { "nct_id": "NCT06461442", "title": "Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Actinic Keratoses" ], "interventions": [ { "name": "Cryotherapy", "type": "PROCEDURE" }, { "name": "5Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-07-01", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06461442" }, { "nct_id": "NCT01505530", "title": "A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "LY2495655", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2011-12", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 5, "location_summary": "Washington D.C., District of Columbia • Dallas, Texas • The Woodlands, Texas + 2 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Dallas", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" }, { "city": "Tyler", "state": "Texas" }, { "city": "Wenatchee", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505530" }, { "nct_id": "NCT05083481", "title": "A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1570", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Trifluridine + Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2021-10-19", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 12, "location_summary": "Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05083481" }, { "nct_id": "NCT04469556", "title": "Pancreatic Adenocarcinoma Signature Stratification for Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Metastatic", "Pancreatic Ductal Adenocarcinoma", "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "Folfirinox", "type": "DRUG" }, { "name": "Gemcitabine/nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Health Network, Toronto", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2020-10-14", "completion_date": "2025-03-05", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469556" }, { "nct_id": "NCT04418895", "title": "Neoadjuvant Therapy for Localized Rectal Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma" ], "interventions": [ { "name": "Chemoradiation", "type": "OTHER" }, { "name": "short course radiation therapy", "type": "RADIATION" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "CAPOX", "type": "DRUG" }, { "name": "fluoropyrimidine +/- oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "RADIATION", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2021-08-13", "completion_date": "2025-05", "has_results": false, "last_update_posted_date": "2021-11-10", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04418895" }, { "nct_id": "NCT00573131", "title": "Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Adenocarcinoma of the Esophagus", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "OncoGel (Paclitaxel gel)", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "esophageal resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2008-01", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 8, "location_summary": "San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573131" }, { "nct_id": "NCT03783936", "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophageal Adenocarcinoma", "Metastasis", "HER-2 Gene Amplification" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5 fluorouracil", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ashwin Somasundaram", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-01-24", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 7, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03783936" }, { "nct_id": "NCT01652482", "title": "Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "MEHD7945A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2012-10", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-14T00:34:07.489Z", "location_count": 19, "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 14 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Luis Obispo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652482" } ] }